新餘國科(300722.SZ):目前還有幾條生產線正在實施改造,今年預計投資1000-1300萬元進行技術改造
格隆匯10月12日丨新餘國科(300722.SZ)在10月12日接受特定對象調研時表示,公司確實有一條生產線技術改造後,由15個人縮減到6個人,這條生產線改造是我們自己完成的,同時我們現在正在開展幾條生產線的技術改造,企業規模的增長若是依賴於員工人數的增長實現增長,這不是一個好的發展方式。所以我們需要進行技術改造,實現“機械化換人、自動化減人、智能化無人、人機隔離”,一方面提高人均效能,另一方面也是安全生產要求。目前還有幾條生產線正在實施改造,今年預計投資1000-1300萬元進行技術改造,明年也還有幾個技術改造項目,爭取在2025年年底整個生產手段能夠有質的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.